Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International)

During the first half of 2008, Morphosys AG plans to set out the shape of its future drug development strategy, following its mega-scale antibody discovery and development deal with Novartis AG, which the company estimates will deliver $1 billion in cash over the next 10 years. (BioWorld International)

During the first half of 2008, Morphosys AG plans to set out the shape of its future drug development strategy, following its mega-scale antibody discovery and development deal with Novartis AG, which the company estimates will deliver $1 billion in cash over the next 10 years. (BioWorld International)